These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29959729)

  • 1. A Genome-Wide Association Study of α-Synuclein Levels in Cerebrospinal Fluid.
    Zhong XL; Li JQ; Sun L; Li YQ; Wang HF; Cao XP; Tan CC; Wang L; Tan L; Yu JT;
    Neurotox Res; 2019 Jan; 35(1):41-48. PubMed ID: 29959729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
    Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
    Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide association study identifies
    Chen J; Yu JT; Wojta K; Wang HF; Zetterberg H; Blennow K; Yokoyama JS; Weiner MW; Kramer JH; Rosen H; Miller BL; Coppola G; Boxer AL;
    Neurology; 2017 Feb; 88(7):669-676. PubMed ID: 28100725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment.
    Korff A; Liu C; Ginghina C; Shi M; Zhang J;
    J Alzheimers Dis; 2013; 36(4):679-88. PubMed ID: 23603399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.
    Mackin RS; Insel P; Zhang J; Mohlenhoff B; Galasko D; Weiner M; Mattsson N
    J Alzheimers Dis; 2015; 43(3):1007-16. PubMed ID: 25125463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide association study identified ATP6V1H locus influencing cerebrospinal fluid BACE activity.
    Hu H; Li H; Li J; Yu J; Tan L;
    BMC Med Genet; 2018 May; 19(1):75. PubMed ID: 29751835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
    Han MR; Schellenberg GD; Wang LS;
    BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.
    Kim S; Swaminathan S; Shen L; Risacher SL; Nho K; Foroud T; Shaw LM; Trojanowski JQ; Potkin SG; Huentelman MJ; Craig DW; DeChairo BM; Aisen PS; Petersen RC; Weiner MW; Saykin AJ;
    Neurology; 2011 Jan; 76(1):69-79. PubMed ID: 21123754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders.
    Li JQ; Bi YL; Shen XN; Wang HF; Xu W; Tan CC; Dong Q; Wang YJ; Tan L; Yu JT;
    Transl Neurodegener; 2020 Nov; 9(1):41. PubMed ID: 33228804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide association study identifies
    Li X; Chu SG; Shen XN; Hou XH; Xu W; Ou YN; Dong Q; Tan L; Yu JT
    Aging (Albany NY); 2019 Nov; 11(21):9862-9874. PubMed ID: 31711042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of cerebrospinal fluid α-synuclein with total and phospho-tau
    Vergallo A; Bun RS; Toschi N; Baldacci F; Zetterberg H; Blennow K; Cavedo E; Lamari F; Habert MO; Dubois B; Floris R; Garaci F; Lista S; Hampel H; ;
    Alzheimers Dement; 2018 Dec; 14(12):1623-1631. PubMed ID: 30055132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide association study identifies two loci influencing plasma neurofilament light levels.
    Li JQ; Yuan XZ; Li HY; Cao XP; Yu JT; Tan L; Chen WA;
    BMC Med Genomics; 2018 May; 11(1):47. PubMed ID: 29747637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CR1 Genetic Variants on Cerebrospinal Fluid and Neuroimaging Biomarkers in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Cohorts.
    Zhu XC; Wang HF; Jiang T; Lu H; Tan MS; Tan CC; Tan L; Tan L; Yu JT;
    Mol Neurobiol; 2017 Jan; 54(1):551-562. PubMed ID: 26742530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation.
    Kauwe JS; Bailey MH; Ridge PG; Perry R; Wadsworth ME; Hoyt KL; Staley LA; Karch CM; Harari O; Cruchaga C; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; ; Fagan AM; Holtzman DM; Morris JC; Goate AM
    PLoS Genet; 2014 Oct; 10(10):e1004758. PubMed ID: 25340798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide association and interaction studies of CSF T-tau/Aβ
    Li J; Zhang Q; Chen F; Meng X; Liu W; Chen D; Yan J; Kim S; Wang L; Feng W; Saykin AJ; Liang H; Shen L;
    Neurobiol Aging; 2017 Sep; 57():247.e1-247.e8. PubMed ID: 28641921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.
    Nho K; Kim S; Horgusluoglu E; Risacher SL; Shen L; Kim D; Lee S; Foroud T; Shaw LM; Trojanowski JQ; Aisen PS; Petersen RC; Jack CR; Weiner MW; Green RC; Toga AW; Saykin AJ;
    BMC Med Genomics; 2017 May; 10(Suppl 1):29. PubMed ID: 28589856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.